Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation Trial With Administration Schedule Exploration Evaluating Single Agent TD001, a PSMA-Targeted Antibody-Drug Conjugate, in Patients With PSMA-Expressing Metastatic Castration-Resistant Prostate Cancer

NCT07258407 is registered in ClinicalTrials.gov with T.O.A.D. Oncology SA as lead sponsor.

NCT NCT07258407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07258407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation Trial With Administration Schedule Exploration Evaluating Single Agent TD001, a PSMA-Targeted Antibody-Drug Conjugate, in Patients With PSMA-Expressing Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
T.O.A.D. Oncology SA
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 30, 2026
Completion date
March 31, 2029
Enrollment
180 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostatic cancer